<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39449300</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2038-8322</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Hematology reports</Title><ISOAbbreviation>Hematol Rep</ISOAbbreviation></Journal><ArticleTitle>Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy.</ArticleTitle><Pagination><StartPage>585</StartPage><EndPage>592</EndPage><MedlinePgn>585-592</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/hematolrep16040057</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In 2019, a new coronavirus disease emerged in Wuhan, China, known as SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, and caused an ongoing pandemic. Symptomatology of the syndrome is variable, with complications extending to hematopoiesis and hemostasis. Approximately a year after onset of the virus, four vaccination formulas became available to the public, based on a viral vector or mRNA technology. These vaccine formulas have been hampered with hematological complications, like vaccine-induced immune thrombotic thrombocytopenia (VITT) and vaccine-related ITP (immune thrombocytopenic purpura). ITP is a disease with autoimmune pathogenesis characterized by antibody production against platelets and an increased hemorrhagic risk. A decent number of cases have been referred to as possible adverse effects of COVID-19 vaccinations.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">in this case report, we present two cases of newly diagnosed ITP after vaccination with ChAdOx1-S (AstraZeneca), with a good response to treatment with thrombopoietin-receptor agonists (TPO-RAs).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">we observed an absence of response after corticosteroids and IVIG therapy and a positive therapeutic outcome on TPO-RA.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">in the ongoing pandemic, there is an urgent need to create therapeutic guidelines for vaccination-related clinical entities and to clarify indications for the vaccination of patients with pre-existing hematological diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salveridou</LastName><ForeName>Konstantina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0001-6141-339X</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Hematology and Palliative Care, Marien Hospital Duesseldorf, 40479 Duesseldorf, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Hematology and Palliative Care, Bethesda Hospital Moenchengladbach, 41061 Moenchengladbach, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzamalis</LastName><ForeName>Theodoros</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Oncology, Hematology and Palliative Care, Marien Hospital Duesseldorf, 40479 Duesseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klaiber-Hakimi</LastName><ForeName>Maika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology, Hematology and Palliative Care, Marien Hospital Duesseldorf, 40479 Duesseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haase</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, Hematology and Palliative Care, Marien Hospital Duesseldorf, 40479 Duesseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gröpper</LastName><ForeName>Stefanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, Hematology and Palliative Care, Marien Hospital Duesseldorf, 40479 Duesseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giagounidis</LastName><ForeName>Aristoteles</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4083-4109</Identifier><AffiliationInfo><Affiliation>Department of Oncology, Hematology and Palliative Care, Marien Hospital Duesseldorf, 40479 Duesseldorf, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Hematol Rep</MedlineTA><NlmUniqueID>101556723</NlmUniqueID><ISSNLinking>2038-8322</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ITP</Keyword><Keyword MajorTopicYN="N">TPO-RA</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>2</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39449300</ArticleId><ArticleId IdType="pmc">PMC11503447</ArticleId><ArticleId IdType="doi">10.3390/hematolrep16040057</ArticleId><ArticleId IdType="pii">hematolrep16040057</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 Dashboard  Center for Systems and Science and Engineering (CSSE) at John Hopkins University. 2022.  [(accessed on 30 January 2022)].  Available online:  https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6.</Citation></Reference><Reference><Citation>Lippi G., Sanchis-Gomar F., Favaloro E.J., Lavie C.J., Henry B.M. Coronavirus Disease 2019_Associated Coagulopathy. Mayo Clin. Proc. 2021;96:203–217. doi: 10.1016/j.mayocp.2020.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.10.031</ArticleId><ArticleId IdType="pmc">PMC7604017</ArticleId><ArticleId IdType="pubmed">33413819</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman S. Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism. Semin. Thromb. Hemost. 2020;46:772–776. doi: 10.1055/s-0040-1710337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1710337</ArticleId><ArticleId IdType="pmc">PMC7645820</ArticleId><ArticleId IdType="pubmed">32392613</ArticleId></ArticleIdList></Reference><Reference><Citation>Uaprasert N., Moonla C., Sosothikul D., Rojnuckarin P., Chiasakul T. Systemic Coagulopathy in Hospitalized Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clin. Appl. Thromb. 2021;27:1076029620987629. doi: 10.1177/1076029620987629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029620987629</ArticleId><ArticleId IdType="pmc">PMC7812392</ArticleId><ArticleId IdType="pubmed">33443456</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulis G., Palmaro A., Montastruc J.L., Godeau B., Lapeyre-Mestre M., Sailler L. Epidemiology of incident immune thrombocytopenia: A nationwide population-based study in France. Blood. 2014;124:3308–3315. doi: 10.1182/blood-2014-05-578336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-05-578336</ArticleId><ArticleId IdType="pubmed">25305203</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrell D.R., Beebe L.A., Vesely S.K., Neas B.R., Segal J.B., George J.N. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am. J. Hematol. 2010;85:174–180. doi: 10.1002/ajh.21616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.21616</ArticleId><ArticleId IdType="pubmed">20131303</ArticleId></ArticleIdList></Reference><Reference><Citation>Cines D.B., Bussel J.B., Liebman H.A., Luning Prak E.T. The ITP syndrome: Pathogenic and clinical diversity. Blood. 2009;113:6511–6521. doi: 10.1182/blood-2009-01-129155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-01-129155</ArticleId><ArticleId IdType="pmc">PMC2710913</ArticleId><ArticleId IdType="pubmed">19395674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuter D.J. Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br. J. Haematol. 2021;195:365–370. doi: 10.1111/bjh.17645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17645</ArticleId><ArticleId IdType="pmc">PMC8239625</ArticleId><ArticleId IdType="pubmed">34075578</ArticleId></ArticleIdList></Reference><Reference><Citation>Perricone C., Ceccarelli F., Nesher G., Borella E., Odeh Q., Conti F., Shoenfeld Y., Valesini G. Immune thrombocytopenic purpura (ITP) associated with vaccinations: A review of reported cases. Immunol. Res. 2014;60:226–235. doi: 10.1007/s12026-014-8597-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-014-8597-x</ArticleId><ArticleId IdType="pubmed">25427992</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C., Kaye J.A., Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br. J. Clin. Pharmacol. 2003;55:107–111. doi: 10.1046/j.1365-2125.2003.01790.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.2003.01790.x</ArticleId><ArticleId IdType="pmc">PMC1884189</ArticleId><ArticleId IdType="pubmed">12534647</ArticleId></ArticleIdList></Reference><Reference><Citation>Isai A., Durand J., Le Meur S., Hidalgo-Simon A., Kurz X. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. Vaccine. 2012;30:7123–7129. doi: 10.1016/j.vaccine.2012.09.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.032</ArticleId><ArticleId IdType="pubmed">23022149</ArticleId></ArticleIdList></Reference><Reference><Citation>David P., Shoenfeld Y. ITP following vaccination. Int. J. Infect. Dis. 2020;99:243–244. doi: 10.1016/j.ijid.2020.07.085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.07.085</ArticleId><ArticleId IdType="pubmed">32763445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N., Maitland H. Acute Immune Thrombocytopenia following administration of Shingrix recombinant zoster vaccine. Am. J. Hematol. 2021;96:E136–E137. doi: 10.1002/ajh.26143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26143</ArticleId><ArticleId IdType="pubmed">33630318</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Leary S.T., Glanz J.M., McClure D.L., Akhtar A., Daley M.F., Nakasato C., Baxter R., Davis R.L., Izurieta H.S., Lieu T.A., et al. The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and Adolescents. Pediatrics. 2012;129:248–255. doi: 10.1542/peds.2011-1111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2011-1111</ArticleId><ArticleId IdType="pubmed">22232308</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Favaloro E.J., Henry B.M., Lippi G. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. Semin. Thromb. Hemost. 2021;47:400–418. doi: 10.1055/s-0041-1727282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1727282</ArticleId><ArticleId IdType="pubmed">33893632</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M., Thachil J. Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy_Either, Neither, or Both. Semin. Thromb. Hemost. 2020;46:781–784. doi: 10.1055/s-0040-1712156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1712156</ArticleId><ArticleId IdType="pmc">PMC7645819</ArticleId><ArticleId IdType="pubmed">32512589</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen J.B., Pasalic L., Hvas A.M. Platelets in Coronavirus Disease 2019. Semin. Thromb. Hemost. 2020;46:823–825. doi: 10.1055/s-0040-1710006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1710006</ArticleId><ArticleId IdType="pmc">PMC7645810</ArticleId><ArticleId IdType="pubmed">32356294</ArticleId></ArticleIdList></Reference><Reference><Citation>Favaloro E.J., Henry B.M., Lippi G. Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature. Semin. Thromb. Hemost. 2021;48:55–71. doi: 10.1055/s-0041-1729856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1729856</ArticleId><ArticleId IdType="pubmed">34130341</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Martínez D., Torres Z., Amezcua-Guerra L.M., Pineda C. Are antiphospholipid antibodies just a common epiphenomenon or are they causative of immune-mediated coagulopathy in COVID-19? Clin. Rheumatol. 2021;40:3015–3019. doi: 10.1007/s10067-021-05724-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05724-5</ArticleId><ArticleId IdType="pmc">PMC8024929</ArticleId><ArticleId IdType="pubmed">33826045</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson C.R., Shi T., Vasileiou E., Katikireddi S.V., Kerr S., Moore E., McCowan C., Agrawal U., Shah S.A., Ritchie L.D., et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat. Med. 2021;27:1290–1297. doi: 10.1038/s41591-021-01408-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01408-4</ArticleId><ArticleId IdType="pmc">PMC8282499</ArticleId><ArticleId IdType="pubmed">34108714</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan G., Liu H., Liang Z., Zhang G., Liu X., Ma L. Vaccine-associated thrombocytopenia. Thromb. Res. 2022;220:12–20. doi: 10.1016/j.thromres.2022.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.09.017</ArticleId><ArticleId IdType="pubmed">36265409</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., Langer F., Makris M., Pai M., Pavord S., Tran H., Warkentin T.E. Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. J. Thromb. Haemost. 2022;20:149–156. doi: 10.1111/jth.15572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15572</ArticleId><ArticleId IdType="pmc">PMC8646430</ArticleId><ArticleId IdType="pubmed">34693641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.J., Cines D.B., Gernsheimer T., Kessler C., Michel M., Tarantino M.D., Semple J.W., Arnold D.M., Godeau B., Lambert M.P., et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am. J. Hematol. 2021;96:534–537. doi: 10.1002/ajh.26132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26132</ArticleId><ArticleId IdType="pmc">PMC8014568</ArticleId><ArticleId IdType="pubmed">33606296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenney B., Stack G. Drug-Induced Thrombocytopenia. Arch. Pathol. Lab. Med. 2009;133:309–314. doi: 10.5858/133.2.309.</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/133.2.309</ArticleId><ArticleId IdType="pubmed">19195976</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecinati V., Principi N., Brescia L., Giordano P., Esposito S. Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum. Vaccines Immunother. 2013;9:1158–1162. doi: 10.4161/hv.23601.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.23601</ArticleId><ArticleId IdType="pmc">PMC3899154</ArticleId><ArticleId IdType="pubmed">23324619</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan R. Antiplatelet Antibodies in Chronic Adult Immune Thrombocytopenic Purpura: Assays and Epitopes. J. Pediatr. Hematol. 2003;25:S57–S61. doi: 10.1097/00043426-200312001-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00043426-200312001-00013</ArticleId><ArticleId IdType="pubmed">14668642</ArticleId></ArticleIdList></Reference><Reference><Citation>France E.K., Glanz J., Xu S., Hambidge S., Yamasaki K., Black S.B., Marcy M., Mullooly J.P., Jackson L.A., Nordin J., et al. Risk of Immune Thrombocytopenic Purpura after Measles-Mumps-Rubella Immunization in Children. Pediatrics. 2008;121:e687–e692. doi: 10.1542/peds.2007-1578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2007-1578</ArticleId><ArticleId IdType="pubmed">18310189</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y., Agmon-Levin N. ‘ASIA’—Autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 2011;36:4–8. doi: 10.1016/j.jaut.2010.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2010.07.003</ArticleId><ArticleId IdType="pubmed">20708902</ArticleId></ArticleIdList></Reference><Reference><Citation>Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y. Vaccines and autoimmunity. Nat. Rev. Rheumatol. 2009;5:648–652. doi: 10.1038/nrrheum.2009.196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2009.196</ArticleId><ArticleId IdType="pubmed">19865091</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmerich F., Bal G., Barakat A., Milz J., Mühle C., Martinez-Gamboa L., Dörner T., Salama A. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br. J. Haematol. 2006;136:309–314. doi: 10.1111/j.1365-2141.2006.06431.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2006.06431.x</ArticleId><ArticleId IdType="pubmed">17156395</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu D., Chen Z., Zhao H., Du W., Xue F., Ge J., Sui T., Wu H., Liu B., Lu S., et al. Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia. Hum. Immunol. 2010;71:586–591. doi: 10.1016/j.humimm.2010.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2010.02.010</ArticleId><ArticleId IdType="pubmed">20153790</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser C., Swinkels M., van Werkhoven E.D., Croles F.N., Noordzij-Nooteboom H.S., Eefting M., Last-Koopmans S.M., Idink C., Westerweel P.E., Santbergen B., et al. COVID-19 vaccination in patients with immune thrombocytopenia. Blood advances. 2022;6:1637–1644. doi: 10.1182/bloodadvances.2021006379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006379</ArticleId><ArticleId IdType="pmc">PMC8709724</ArticleId><ArticleId IdType="pubmed">34941989</ArticleId></ArticleIdList></Reference><Reference><Citation>Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus. 2009;18:1217–1225. doi: 10.1177/0961203309345724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309345724</ArticleId><ArticleId IdType="pubmed">19880572</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee S., Banerjee M. Immune Thrombocytopenia Secondary to COVID-19: A Systematic Review. SN Compr. Clin. Med. 2020;2:2048–2058. doi: 10.1007/s42399-020-00521-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00521-8</ArticleId><ArticleId IdType="pmc">PMC7501509</ArticleId><ArticleId IdType="pubmed">32984764</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi X., Gatti P., Papoian T. Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov. Today. 2017;22:823–833. doi: 10.1016/j.drudis.2017.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2017.01.013</ArticleId><ArticleId IdType="pubmed">28159625</ArticleId></ArticleIdList></Reference><Reference><Citation>Jason T.L., Koropatnick J., Berg R.W. Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. 2004;201:66–83. doi: 10.1016/j.taap.2004.04.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2004.04.017</ArticleId><ArticleId IdType="pubmed">15519609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh O., Tarawneh H. Immune thrombocytopenia in a 22-year-old post COVID-19 vaccine. Am. J. Hematol. 2021;96:E133. doi: 10.1002/ajh.26106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26106</ArticleId><ArticleId IdType="pmc">PMC8014773</ArticleId><ArticleId IdType="pubmed">33476455</ArticleId></ArticleIdList></Reference><Reference><Citation>Toom S., Wolf B., Avula A., Peeke S., Becker K. Familial thrombocytopenia flare-up following the first dose of mRNA-1273 COVID-19 vaccine. Am. J. Hematol. 2021;96:E134. doi: 10.1002/ajh.26128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26128</ArticleId><ArticleId IdType="pmc">PMC8014325</ArticleId><ArticleId IdType="pubmed">33580970</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards D.K., Jasny E., Yoon H., Horscroft N., Schanen B., Geter T., Fotin-Mleczek M., Petsch B., Wittman V. Adjuvant effects of a sequence-engineered mRNA vaccine: Translational profiling demonstrates similar human and murine innate response. J. Transl. Med. 2017;15:1–18. doi: 10.1186/s12967-016-1111-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-016-1111-6</ArticleId><ArticleId IdType="pmc">PMC5210268</ArticleId><ArticleId IdType="pubmed">28049494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndeupen S., Qin Z., Jacobsen S., Bouteau A., Estanbouli H., Igyártó B.Z. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24:103479. doi: 10.1016/j.isci.2021.103479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103479</ArticleId><ArticleId IdType="pmc">PMC8604799</ArticleId><ArticleId IdType="pubmed">34841223</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>